ArticleBMC microbiology2025
Establishing translational performance standards for TB therapy using rifampicin-based regimens in a male and female high-burden murine model.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pretomanid vs delamanid in a bedaquiline-linezolid regimen: efficacy in a high-burden tuberculosis mouse model.Antimicrobial agents and chemotherapy · 2026Article
- NTM-host matched infection models for the classification of drug efficacy against rapid and slow growing nontuberculous mycobacteria species.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEstablishing efficacy benchmarks in preclinical tuberculosis (TB) models is essential for optimizing and prioritizing therapeutic regimens. However, standardized classification methods for comparing high-performing regimens are currently lacking. This study defines a quantitative framework utilizing rifampicin-based regimens in a high-burden aerosol BALB/c mouse model, incorporating both male and female mice to assess potential sex-specific treatment responses.
methodsMice were infected with Mycobacterium tuberculosis Erdman strain and treated for 4 or 8 weeks with rifampicin (R), rifampicin plus pyrazinamide (RZ), or rifampicin, isoniazid, and pyrazinamide (RHZ). Treatments were administered orally five days a week. The bacterial burden in the lungs and spleens was quantified by CFU enumeration. Pharmacokinetic analysis confirmed drug exposures. To establish classification benchmarks, treatment efficacy was evaluated using quartile performance thresholds and Cohen's d effect size analysis.
resultsAll regimens reduced lung CFUs compared to controls. RHZ demonstrated a high benchmark, achieving mean reductions of 3 ± 0.5 Log
conclusionThis study establishes a quantitative framework for evaluating TB treatments in a preclinical high-burden BALB/c mouse model. The dual-metric classification framework provides sex-inclusive, quantitative performance criteria that enhance the translational relevance of preclinical efficacy studies. This approach sets relative benchmarks that support the comparative evaluation of novel regimens and helps to align preclinical performance with clinical expectations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.